Clin Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Diabetes 25:64-65, 2007
DOI: 10.2337/diaclin.25.2.64
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pignone, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pignone, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Landmark Study

Initial Oral Therapy for Patients With Type 2 Diabetes

Michael Pignone, MD, MPH

The first 20% of the full text of this article appears below.


   STUDY
 
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med355 : 2427-2443,2006[Abstract/Free Full Text]


   SUMMARY
 
Design. Double-blind, randomized, controlled trial comparing initial therapy with rosiglitazone, metformin, or glyburide for patients with type 2 diabetes.

Subjects. A total of 4,360 patients aged 30-75 years with fasting plasma glucose levels from 126 to 180 mg/dl when treated with lifestyle change recommendations alone. Patients with clinically significant liver disease, renal impairment, unstable or severe angina, congestive heart failure, or uncontrolled hypertension were excluded.

Methods. Patients were recruited from 488 centers in North America and Europe between April 2000 and June 2002. Participants received one of three initial regimens: 4 mg of rosiglitazone daily, 500 mg of metformin daily, or 2.5 mg of glyburide daily. Medication dosages were titrated upward at each visit if fasting plasma glucose was > 140 . . . [Full Text of this Article]


   COMMENTARY
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.